Sandoz acquires Cimerli biosimilar (ranibizumab-eqrn) business from Coherus BioSciences.
Sandoz, has signed an agreement to acquire the US biosimilar ranibizumab Cimerli (ranibizumab-eqrn) from Coherus BioSciences, Inc. for an upfront cash purchase payment of $ 170 million
This is inclusive of a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, as well as access to proprietary commercial software.
Keren Haruvi, President Sandoz North America, said: “I am pleased that we can add another high-value product to the growing Sandoz biosimilar portfolio, further strengthening our existing ophthalmology franchise. The addition of Cimerli reinforces our commitment to biosimilars and represents a huge step towards our goal of pioneering patient access to more affordable and much-needed medicines in the US.”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.